WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/011941    International Application No.:    PCT/US2006/027862
Publication Date: 25.01.2007 International Filing Date: 18.07.2006
C07K 16/28 (2006.01), A61P 37/00 (2006.01), A61P 11/06 (2006.01), A61K 39/395 (2006.01), G01N 33/68 (2006.01), G01N 33/577 (2006.01), C12N 15/13 (2006.01), C12N 5/10 (2006.01)
Applicants: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US) (For All Designated States Except US).
MEDAREX INC. [US/US]; 707 State Road, Princeton, NJ 08540 (US) (For All Designated States Except US).
SIU, Gerald [US/US]; (US) (For US Only).
SHEN, Wenyan [CA/US]; (US) (For US Only).
YOSHINAGA, Steven, Kiyoshi [US/US]; (US) (For US Only).
HUANG, Haichun [US/US]; (US) (For US Only)
Inventors: SIU, Gerald; (US).
SHEN, Wenyan; (US).
YOSHINAGA, Steven, Kiyoshi; (US).
HUANG, Haichun; (US)
Agent: DERRY, Jason, J.; MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US)
Priority Data:
60/700,265 18.07.2005 US
Abstract: front page image
(EN)This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RPl antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RPl antibodies are also provided.
(FR)L'invention concerne des anticorps qui interagissent avec la protéine 1 apparentée à B7 (B7RP1) ou qui se lient à celle-ci, ainsi que des anticorps qui se lient à B7RP1 ou qui en neutralisent la fonction. L'invention concerne également des compositions pharmaceutiques de ces anticorps et des méthodes destinées à neutraliser la fonction de B7RP1, notamment pour le traitement de troubles immunitaires (par ex., réponse immunitaire inappropriée), par administration d'une dose pharmaceutiquement efficace d'anticorps anti-B7RP1. L'invention se rapporte en outre à des méthodes destinées à détecter la concentration de B7RP1 dans un échantillon au moyen d'anticorps anti-B7RP1.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)